Quick Answer
AXIM BIOTECHNOLOGIES, INC. reported Total Revenue of $39.5 thousand for fiscal year 2023.
AXIM BIOTECHNOLOGIES, INC. — Key Financials by Year
| Metric | 2023 | 2022 | 2021 | 2020 | 2018 | 2017 |
|---|---|---|---|---|---|---|
| Total Revenue | $39.5K +345.3% |
$8.9K -85.3% |
$60.5K | — | $195.6K +311.2% |
$47.6K +1.1% |
| Net Income | -$8.06M -29.1% |
-$6.24M +61.1% |
-$16.03M | — | -$6.75M -62.1% |
-$4.17M +28.3% |
| Diluted EPS | -$0.04 +0.0% |
-$0.04 -133.3% |
$0.12 | — | — | — |
| Total Assets | $4.12M -2.1% |
$4.21M -20.9% |
$5.32M | — | $2.09M -4.7% |
$2.19M +51.3% |
| Cash and Equivalents | — | $47.3K -89.6% |
$453.0K | — | $1.81M -12.3% |
$2.06M +188.5% |
| Stockholders Equity | -$7.66M -58.7% |
-$4.83M -106.4% |
-$2.34M -249.3% |
$1.57M | -$6.08M +3.2% |
-$6.28M -165.0% |
| R&D Expense | $125.5K -18.3% |
$153.7K -46.0% |
$284.9K | — | $2.06M +52.0% |
$1.35M +474.3% |
| Operating Income | -$2.75M +40.9% |
-$4.65M +66.7% |
-$13.97M | — | -$5.04M -59.9% |
-$3.15M +16.2% |
| Gross Profit | — | — | — | — | $187.1K +3867.4% |
$4.7K +104.4% |
| Shares Outstanding | 245.93M +27.8% |
192.44M +39.3% |
138.10M | — | 59.58M +9.2% |
54.56M +3.9% |
Most Recent Quarter
| Metric | Quarter Ending | Value | YoY | QoQ |
|---|---|---|---|---|
| Total Revenue | June 30, 2024 | $17.5K | +76.0% | -67.0% |
| Net Income | June 30, 2024 | -$2.27M | +39.0% | -676.5% |
| Diluted EPS | June 30, 2024 | -$0.01 | +50.0% | -900.0% |
| Total Assets | June 30, 2024 | $3.73M | -12.2% | -5.3% |
| Cash and Equivalents | March 31, 2023 | $53.5K | -86.9% | +13.2% |
| Stockholders Equity | June 30, 2024 | -$9.53M | +2.2% | -28.0% |
| R&D Expense | June 30, 2024 | $4.1K | -88.1% | -73.8% |
| Operating Income | June 30, 2024 | -$569.4K | +18.4% | -40.8% |
| Gross Profit | June 30, 2024 | $15.7K | +58.5% | +58.5% |
| Shares Outstanding | June 30, 2024 | 294.46M | +29.3% | +5.8% |
- AXIM BIOTECHNOLOGIES, INC. reported Total Revenue of $39.5 thousand for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +345.3% in Total Revenue compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Net Income of -$8.06 million for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -29.1% in Net Income compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Diluted EPS of $0.04 per share (loss) for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +0.0% in Diluted EPS compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Total Assets of $4.12 million for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -2.1% in Total Assets compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Cash and Equivalents of $47.3 thousand for fiscal year 2022.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -89.6% in Cash and Equivalents compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Stockholders Equity of -$7.66 million for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -58.7% in Stockholders Equity compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported R&D Expense of $125.5 thousand for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed a decrease of -18.3% in R&D Expense compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Operating Income of -$2.75 million for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +40.9% in Operating Income compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Gross Profit of $187.1 thousand for fiscal year 2018.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +3867.4% in Gross Profit compared to the prior fiscal year.
- AXIM BIOTECHNOLOGIES, INC. reported Shares Outstanding of 245.93 million shares for fiscal year 2023.
- AXIM BIOTECHNOLOGIES, INC. showed an increase of +27.8% in Shares Outstanding compared to the prior fiscal year.
- All figures are sourced from SEC EDGAR XBRL filings, last verified June 17, 2026.
Last verified: